Category Archives: Public Policy

Latest From Public Policy

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor


India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Mayo v. Prometheus: BIO Statement on Supreme Court Decision

U.S. Supreme Court

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization We are surprised and disappointed in the Court’s decision, which disregarded the considered judgment of the Executive Branch experts and numerous amici such as BIO, who warned about the unintended consequences of attempting to use patent eligibility as a basis to strike down these patents for biomarker-based diagnostic methods. While we are still analyzing the opinion, we are concerned that it introduces new and Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Patent “Ever-Greening”: Novartis Confronts Patent Myth in India


India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug from receiving a patent unless the new form is significantly more effective than the previously-known form. This provision aims to accomplish one task: stop patent “ever-greening.”  This issue has risen to prominence lately as the New York Times reports on the Novartis suit challenging patent ever-greening requirements in India’s Supreme Court. So what is patent ever-greening?  Opponents claim that corporations Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

BIO IP Counsels Conference Agenda Topics


Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda topics are below. The Decline of Process Patents: This session will examine the enforceability of process claims and how it has led to the recent controversy around divided infringement. Unlike claims to machines, manufactures, and compositions, process claims can be divided up by different actors, or by jurisdiction, and conceivably even by time.  Right now the focus is on different Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Patents for Humanity


By David Kappos, Director of the United States Patent and Trademark Office (USPTO) Originally Published on USPTO Director’s Forum Sweeping revolutions in technology continue to fundamentally redefine the way we connect with one another and interact with the world. Today, an entrepreneur can do business with a remote village across an ocean just as quickly as a student in Boston can video-conference with a professor in Beijing. Political rallies can be organized by the click of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,